Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Receivables - Net: 2017-2025

Historic Receivables - Net for Aclaris Therapeutics (ACRS) over the last 7 years, with Jun 2025 value amounting to $194,000.

  • Aclaris Therapeutics' Receivables - Net fell 72.29% to $194,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $194,000, marking a year-over-year decrease of 72.29%. This contributed to the annual value of $318,000 for FY2024, which is 6.71% up from last year.
  • Per Aclaris Therapeutics' latest filing, its Receivables - Net stood at $194,000 for Q2 2025, which was down 22.40% from $250,000 recorded in Q1 2025.
  • Aclaris Therapeutics' 5-year Receivables - Net high stood at $939,000 for Q2 2021, and its period low was $194,000 during Q2 2025.
  • Over the past 3 years, Aclaris Therapeutics' median Receivables - Net value was $344,500 (recorded in 2023), while the average stood at $393,900.
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 62.41% in 2024, then crashed by 72.29% in 2025.
  • Over the past 5 years, Aclaris Therapeutics' Receivables - Net (Quarterly) stood at $623,000 in 2021, then decreased by 22.31% to $484,000 in 2022, then slumped by 38.43% to $298,000 in 2023, then climbed by 6.71% to $318,000 in 2024, then slumped by 72.29% to $194,000 in 2025.
  • Its Receivables - Net was $194,000 in Q2 2025, compared to $250,000 in Q1 2025 and $318,000 in Q4 2024.